STOCK TITAN
  1. Home
  2. Sec-filings
  3. CERO
  4. [8-K] CERo Therapeutics Holdings, Inc. Reports Material Event

[8-K] CERo Therapeutics Holdings, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock CERO logo
CERo Therapeutics

NASDAQ:CERO

CERO Rankings

#10960 Ranked by Market Cap
N/A Ranked by Dividends

CERO Latest News

Jun 23, 2025
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
Jun 17, 2025
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)
Jun 11, 2025
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
Jun 6, 2025
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
Jun 2, 2025
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236

CERO Latest SEC Filings

Jul 14, 2025
[424B3] CERo Therapeutics Holdings, Inc. Prospectus Filed Pursuant to Rule 424(b)(3)
Jul 14, 2025
[8-K] CERo Therapeutics Holdings, Inc. Reports Material Event
Jul 8, 2025
[8-K] CERo Therapeutics Holdings, Inc. Reports Material Event
Jul 2, 2025
[424B3] CERo Therapeutics Holdings, Inc. Prospectus Filed Pursuant to Rule 424(b)(3)
Jun 30, 2025
[8-K] CERo Therapeutics Holdings, Inc. Reports Material Event

CERO Stock Data

4.57M
473.35k
18.77%
4.47%
9.66%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO